CHAARTED (E3805)
The first trial to show chemotherapy at the start of hormone therapy prolongs life in metastatic prostate cancer.
Overview
CHAARTED, ECOG-ACRIN trial E3805, NCT00309985, reported in 2015, was the first trial to show that giving docetaxel at the start of hormone therapy prolongs life in metastatic hormone-sensitive prostate cancer. It randomised 790 men to androgen deprivation with or without docetaxel and met its primary overall survival endpoint, but in long-term follow-up the benefit was confined to men with high-volume disease. Nuclide links it to prostate cancer, docetaxel and Christopher J. Sweeney, and the result was replicated by arm C of the STAMPEDE platform, with the concentration of benefit in high-volume disease shaping how that distinction is used. Whether chemotherapy still earns its place now that triplet regimens and PSMA radioligands have entered this setting is the open question. Docetaxel has its own page.
- Median 57.6 vs 44 months with ADT + docetaxel compared with ADT alone; about 13.6 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 39 percent lower chance of the event at any given time (hazard ratio 0.61, likely range 0.47 to 0.8).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Metastatic hormone-sensitive prostate cancer: ADT + docetaxel vs ADT. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
790 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | ADT + docetaxel | 397 | 57.6 months | 0.61 (0.47 to 0.8) | <0.001 | link |
| ADT alone | 393 | 44 months |
Similar pages
not linked directly; found by shared links- TrialUpFrontPSMA
Shares Docetaxel, Metastatic hormone-sensitive prostate cancer.
- TrialPhase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Shares Docetaxel, Prostate cancer.
- TrialSTAMPEDE
Shares Docetaxel, Metastatic hormone-sensitive prostate cancer, Prostate cancer.
- IndicationNeuroendocrine and small-cell prostate cancer
Shares Docetaxel, Metastatic hormone-sensitive prostate cancer, Prostate cancer.
- TermOligometastatic disease
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.
- TrialThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Shares Docetaxel, Prostate cancer.
- TrialPSMAddition
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.
- IndicationNon-metastatic castration-resistant prostate cancer
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.